AgomAb Therapeutics NV (AGMB)
Nasdaq: AGMB · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2024
Income statement, as filed
In thousands of euros (EUR), as filed; per-share figures in euros; share counts. The fiscal year ends in December.The Form 20-F filed Apr 23, 2026 for the period ended Dec 31, 2025 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Apr 23, 2026 | · | · |
| Research and development | 48,877 | 39,310 | 26,311 |
| General and administrative | 12,791 | 10,133 | 6,097 |
| Total operating expenses | 61,668 | 49,443 | 32,408 |
| Operating income | -59,275 | -48,021 | -31,190 |
| Finance costs | 133 | 357 | 86 |
| Finance income | 1,718 | 1,267 | 303 |
| Income before income taxes | -62,547 | -46,263 | -12,009 |
| Income tax expense | · | 4 | -619 |
| Net income | -62,547 | -46,267 | -11,390 |
| Earnings per share, basic | -143.22 | -107.09 | -35.63 |
| Earnings per share, diluted | -143.22 | -107.09 | -35.63 |
| Weighted average shares, basic | 541,126 | 541,126 | 541,126 |
| Weighted average shares, diluted | 541,126 | 541,126 | 541,126 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
ifrs-full:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
ifrs-full:OperatingExpenseOperating income profit from running the business, before interest and tax
ifrs-full:ProfitLossFromOperatingActivitiesFinance costs what its borrowing cost
ifrs-full:FinanceCostsFinance income what its cash and investments earned
ifrs-full:FinanceIncomeIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares